Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats

Prostate

Volumn 71, Issue 9, 2011, Pages 998-1011

  Feldmann, Anja ^a   Stamova, Slava ^a   Bippes, Claudia C ^a   Bartsch, Holger ^a   Wehner, Rebekka ^a   Schmitz, Marc ^a,b   Temme, Achim ^c   Cartellieri, Marc ^a   Bachmann, Michael ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

immunotherapy; prostate cancer; single chain bispecific antibodies; T cell targeting

Indexed keywords

BISPECIFIC ANTIBODY; CYTOKINE; PROSTATE STEM CELL ANTIGEN;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; COMPARATIVE STUDY; CROSS LINKING; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TUMOR CELL;

ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNIZATION, PASSIVE; MALE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; T-LYMPHOCYTES;

EID: 79955631811     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21315     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Coen JJ, Zietman AL, Thakral H, Shipley WU,. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199-3205. (Pubitemid 34831515)
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004; 172: 910-914. (Pubitemid 39096421)
4. Miyamoto H, Messing EM, Chang C,. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61: 332-353. (Pubitemid 39571710)
5. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45. (Pubitemid 33741879)
6. Adams GP, Weiner LM,. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157. (Pubitemid 41486396)
7. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R,. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-1496. (Pubitemid 32708610)
8. Li Y, Zhu Z,. Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther 2007; 7: 319-330. (Pubitemid 46383475)
9. Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Millowsky MI, Bander NH,. Antibody-based therapeutics: Focus on prostate cancer. Cancer Metastasis Rev 2005; 24: 521-537. (Pubitemid 43096999)
10. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P,. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
11. Blanco B, Holliger P, Vile RG, Varez-Vallina L,. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070-1077. (Pubitemid 36871424)
12. Buhler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsasser-Beile U,. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008; 57: 43-52. (Pubitemid 350043647)
13. Buhler P, Molnar E, Dopfer EP, Wolf P, Gierschner D, Wetterauer U, Schamel WW, Elsasser-Beile U,. Target-dependent T-cell activation by coligation with a PSMA × CD3 diabody induces lysis of prostate cancer cells. J Immunother 2009; 32: 565-573.
14. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M,. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60: 4336-4341. (Pubitemid 32103606)
15. D'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC,. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009; 33: 465-473.
16. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC,. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003; 170: 4397-4402. (Pubitemid 36428210)
17. Holliger P, Winter G,. Engineering bispecific antibodies. Curr Opin Biotechnol 1993; 4: 446-449. (Pubitemid 23250384)
18. Kipriyanov SM,. Generation of bispecific and tandem diabodies. Methods Mol Biol 2009; 562: 177-193.
19. Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR,. Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 2001; 18: 31-40. (Pubitemid 32776592)
20. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da SA, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA,. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 2005; 65: 2882-2889. (Pubitemid 40490092)
21. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP,. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236: 229-238.
22. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M,. Advances in specific immunotherapy for prostate cancer. Eur Urol 2008; 53: 694-708.
23. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON,. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-1740. (Pubitemid 28103463)
24. Raff AB, Gray A, Kast WM,. Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett 2009; 277: 126-132.
25. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A,. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001; 98: 2658-2663. (Pubitemid 32209538)
26. Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H,. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62: 2546-2553. (Pubitemid 34462733)
27. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE,. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007; 30: 396-405. (Pubitemid 46684429)
28. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE,. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19: 1288-1296. (Pubitemid 30160621)
29. Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M,. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60: 5522-5528.
30. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A,. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007; 67: 1121-1131. (Pubitemid 46983341)
31. Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D,. Universal PCR amplification of mouse immunoglobulin gene variable regions: The design of degenerate primers and an assessment of the effect of DNA polymerase 3â to 5â exonuclease activity. J Immunol Methods 2000; 233: 167-177. (Pubitemid 30058245)
32. Carmo-Fonseca M, Pfeifer K, Schroder HC, Vaz MF, Fonseca JE, Muller WE, Bachmann M,. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 1989; 185: 73-85. (Pubitemid 19284956)
33. MÃlhÃj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA,. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007; 44: 1935-1943.